Co-Radiotherapy with Tyrosine Kinase Inhibitors Might Benefit Survival in Hepatoma Patients with Portal Vein Tumor Thrombosis

In this series, 26.9% (43/160) of HCC patients with PVTT underwent combination treatment with TKIs and RT, achieving a median survival of 15.0 months. The contributions of RT were 20% disease control rate and may extend the duration of TKIs use. Therefore, all candidates without contraindications should be considered for combination treatment.